Comparison of Treatment Adherence and Toxicities of HIV Positive patients vs. HIV Negative Cervical Cancer patients in India. - THRIVE

CRDF Global0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年4月4日

试验速览

暂无简介。

•1. Patients with newly biopsy proven squamous carcinoma or adenocarcinoma of the uterine cervix, FIGO stage IB2-IIIB in whom curative CTRT is planned.
•2. Patients with lower paraortic lymph nodes (below the level of L2 vertebra) would be included in the study.
•3. Staging would include clinical examination, CT/MR imaging of the abdomen and pelvis and chest radiography.
•4. All patients would undergo baseline blood investigations, which include complete blood count (CBC), renal function tests, liver functions test and viral marker testing which include HIV, Hepatitis B and Hepatitis C.
•5. Patients with pre-existing HIV positive status will have CD4 counts and HIV viral load evaluated prior to the initiation of cancer directed therapy.
•6. Report of CD4 counts done within the prior 6 months of initiating treatment would be accepted. Patients with newly detected HIV positive status would be counseled and directed to HAART clinic, and CD4 counts/ HIV viral load will be evaluated prior to initiation of HAART and cancer treatment.
•7. Additional eligibility criteria include: age >= 18 years, Karnofsky performance status >= 70.

•1. Patients with active tuberculosis, which would preclude curative treatment or history of previous malignancy.

发起方

CRDF Global